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Human T-cell lymphotropic virus type-1 (HTLV-1) is a type C retrovirus 
endemic to tropical areas. Most infected people are asymptomatic 
carriers, but an estimated 0.25% - 2% of carriers develop a progressive 
myelopathy, known as HTLV-associated myelopathy (HAM) or tropical 
spastic paraparesis (TSP).1,2 HTLV-2 is more common among intravenous 
drug abusers, and may present with a clinical picture similar to HAM.2 
During the last two decades, the HIV pandemic has influenced 
the spectrum of neurological disorders markedly – up to 40% 
of patients with HIV infection clinically show neurological 
disorders,3 and neuropathological abnormalities are even more 
common. Co-infections of HIV and HTLV-1 have been described4,5 
and in South Africa a high prevalence of HAM has been found 
in KwaZulu-Natal,5 with up to 36% of patients showing HIV 
co-infection. A study from Brazil reported on patients with HIV 
and HAM4 but did not directly compare patients with and without 
HIV infection. 
Comparison of HTLV-associated myelopathy (HAM) 
in HIV-positive and HIV-negative patients at a tertiary 
South African hospital
C-M Schutte, T Townsend, R Van Coller, S Olorunju
Department of Neurology, Steve Biko Academic Hospital, Pretoria
C-M Schutte, M Med (Neurol), MD
T Townsend, M Med (Neurol),FCN
R Van Coller, M Med (Neurol)
Medical Research Council, Pretoria
S Olorunju, PhD
Corresponding author: C-M Schutte (cschutte@meic.up.ac.za)
Background. HTLV-1 associated myelopathy (HAM), or tropical spastic paraparesis, is caused by a retrovirus, the human T-cell 
lymphotropic virus (HTLV). Although patients with HAM and HIV infection have been described, to our knowledge no direct comparison 
has been made between patients who are HIV positive and suffering from HAM (HHAM) v. those who are HIV negative and suffering 
from HAM.
Aim. We aimed to compare clinical and radiological findings in HIV-positive and -negative patients with HAM.
Methods. Adult patients who presented to the Neurology Unit at the Steve Biko Academic Hospital from May 2005 to June 2012 with a 
progressive myelopathy and HTLV seropositivity were retrospectively identified and their clinical and radiological data were collected and 
reviewed.
Results. 21 patients with HAM were identified, of whom 9 were HIV-positive and 11 HIV-negative. One patient, whose HIV status had 
not been established, was not included in the study. Although the trend did not reach statistical significance, co-infected patients tended to 
present at an earlier age (HHAM 6/9 (66%) <40 years old; HAM 2/11 (18%) <40 years old) and presented to hospital earlier (HHAM 6/9 
(66%) < 3 years symptomatic; HAM 7/11 (63%) > 3 years symptomatic). Cord atrophy occurred in 7/8 dually infected patients and 8/10 
HIV-negative patients.
Conclusion. Although the study is limited by the small number of patients, co-infected patients tended to have a younger age of onset and 
to present to hospital sooner, and thoracic cord atrophy was very common.
S Afr Med J 2013;103(1):43-46. DOI:10.7196/SAMJ.5298
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We aimed to evaluate the number of patients with HAM seen at 
the Neurology Department of the Steve Biko Academic Hospital, a 
tertiary hospital in Gauteng Province, and to compare the clinical and 
radiological findings of patients who were co-infected with HIV with 
those who were HIV negative. 
Patients and methods
Patients were identified retrospectively from a list of patients with 
positive HTLV-1 serology who presented to the National Health 
Laboratory Services (NHLS) at the Steve Biko Academic Hospital, 
from May 2005 to June 2012. To ascertain which of these seropositive 
patients had presented to the hospital’s Department of Neurology, the 
department’s electronic database was consulted. Patients included in 
the study were those 13 years and older, with signs and/or symptoms 
indicative of possible spinal cord pathology, who had an HIV test 
done during investigation. Patients excluded were those who had not 
undergone an HIV test, or who had another recognised aetiology that 
could better account for symptoms and signs. 
The study was approved by the Ethics Committee of the University 
of Pretoria.
The serology for HTLV-1 detection was performed with ELISA 
by the NHLS. The spinal cord diameters were measured at level T7 
on MRI by a blinded observer who had no access to the patients’ 
clinical information. The data was analysed to determine summary 
statistics and proportions, and the proportions were compared using 
an independent t-test. Meanwhile, comparison for continuous data 
was undertaken using t-tests for independent samples. Stata 12 was 
the software used.
Results
The records showed 73 patients had positive serology for HTLV-1, of 
whom 25 were seen at the Department of Neurology with signs of a 
myelopathy. Of these, 20 were included in the study: 9 tested positive 
for HIV, and 11 tested negative. Of the 5 patients who were excluded, 
4 had alternative aetiologies for their suspected myelopathy: 1 (HIV-
negative) was found to have a profound vitamin B12 deficiency, and 
3 had spinal tuberculosis. The 5th patient had HAM but had not had 
not undergone an HIV test. 
The clinical data of the patients are presented in Table 1 (HIV-
negative patients with HAM) and Table 2 (HIV-positive patients with 
HAM).
 The HIV-negative group consisted of 8 men and 3 women between 
21 and 57 years of age, with a mean of 43,7 ±8,61 years. Minimum 
duration of symptoms was 4 months and maximum 14 years; most 
patients (7/11) had been symptomatic for 3 years or more. Sphincter 
disturbances were common, occurring in 8/11 patients (72%), and 
sensory complaints were noted in 9/10. Radiological reports noted 
atrophy of the cord on MRI in 6 patients, swelling of the cord in 














1 M 48 144 2 Y N NA
2 M 47 48 3 Y Y 4,4
3 M 44 9 3 Y Y 9,6
4 M 43 4 2 N NA 8,8
5 F 21 12 4 N Y 5,1
6 M 47 72 4 Y Y 4,5
7 F 43 36 3 N Y 3,8
8 M 51 168 1 Y Y 4,0
9 M 57 36 3 Y Y 4,2
10 M 41 156 4 Y Y 5,4
11 F 39 24 3 Y Y 4,0
Power grading is by MRC (6) grading scale out of 5; proximal muscle groups of the lower limbs are reflected; Y = yes, N = no, NA = not available.
















1 M 34 4 3 Y Y NA 5
2 M 42 6 5 Y Y 6,2 27
3 M 32 5 4 Y N 6,7 31
4 F 36 96 4 Y N 4,3 300
5 F 25 11 4 Y NA 4,4 484
6 M 36 3 3 Y Y 5,7 148
7 F 45 36 4 Y Y 4,1 1076
8 F 31 24 2 Y Y 2,9 635
9 F 49 96 2 Y Y 5,1 580
Power grading is by MRC (6) grading scale out of 5; proximal muscle groups of the lower limbs are reflected; Y = yes, N = no, NA = not available.
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one and evidence of possible transverse myelitis in one. A blinded 
observer measured cord diameter at level T7, yielding values ranging 
from 3.8 mm to 9.6 mm (normal: 6.5 mm – 9.5 mm), with a mean 
of 5.4 mm. Values <5 mm, implying severe atrophy, were measured 
in 60% of patients.
Five females and four males were seen in the HIV-positive group. 
Their ages ranged from 25 to 49 years with a mean of 36.6 ± 7.06 
years, but though this was lower than in the HIV-negative group, no 
evidence of a statistically significant difference with respect to age 
could be demonstrated. Symptoms had been present for 3 months 
to 8 years, with 66% of patients symptomatic for less than 3 years. 
Sphincter disturbances were present in all patients, and 75% had 
sensory complaints. A trend towards statistical significance (p<0.055) 
between patients <40 years old and >40 years old was observed in 
proportion to sensory symptoms: all older patients had sensory 
symptoms, compared with half of the younger ones. 
Patients’ CD 4 counts ranged from 5 to 1 076 x 106/l, while 56% had 
counts of less than 350 x 106/l. Two patients were on highly active anti-
retroviral therapy (HAART) at presentation. Atrophy of the cord was 
reported on MRI studies in 4 patients, and a transverse myelitis picture 
in 1. When the thoracic cord was measured at level T7, the values ranged 
from 2.9 mm to 6.7 mm (mean: 4.9 mm). Thus, 7/8 patients had cord 
atrophy, and values of <5mm were seen in 50% of patients (see Fig. 
1). There was no evidence of statistical difference in the proportion of 
patients with cord atrophy in the HIV-positive v. the HIV-negative group.
Discussion
HTLV-associated myelopathy was first described in the 1950s in the 
Caribbean,7 but it was only in 1985 that the condition was linked with 
antibodies to the retrovirus known as HTLV.8 HAM is a progressive 
neurodegenerative disease that primarily affects the spinal cord and 
brain. Risk factors for developing an HTLV-associated myelopathy 
are the same as those for the transmission of HIV, including younger 
age of initiation of sexual intercourse and multiple sexual partners.9 
Patients present with a slowly progressive paraparesis affecting the 
lower limbs10 with a cumulative risk of 1.7% of developing HAM by 
the age of 75 years if infected with the virus.11 Other clinical features 
include lumbar pain, detrusor instability, and minor sensory changes, 
especially paraesthesias and loss of vibration sense.12 In our study, the 
patients singly infected with HTLV showed a disease progression and 
clinical signs and symptoms in keeping with this classic description.
Our study showed that co-infected patients had a more rapid 
progression of symptoms that led to an earlier hospital visit. The 
duration of symptoms in more than half of our patients was less than a 
year – a finding not documented in other studies. The clinical picture 
in the dually infected patients may reflect virus-virus interaction.13 
Dually infected patients have higher levels of HTLV antigen and tax/
rex RNA expression in peripheral blood mononuclear cells, thereby 
up-regulating HTLV viral message and portending HTLV-associated 
neurological disease.14 
Patients in a previous study by Beilke et al.15 had high CD 4 counts, 
ranging from 890 - 1 613 x 106/l. However, our study shows that HAM 
can occur at any stage of immune suppression: CD 4 counts ranged 
from 5 to 1 076 x 106/l, and most of our patients had CD 4 counts 
of less than 350 x 106/l. It is unlikely that any of the patients had 
HIV-associated vacuolar myelopathy since the characteristic lesions 
(hyperintensities in the posterior and lateral columns) were not noted 
on MRI. About half of all patients with HAM currently seen at the 
Steve Biko Academic Hospital are infected with HIV, compared with 
33% in KwaZulu-Natal.5 Co-infection of HTLV-1 and HIV in patients 
with HAM has been mentioned in several studies.4,5,14,15 According to 
Berger et al.,16 patients co-infected with HIV/HTLV are at increased 
risk for developing HAM. Elsewhere, a Brazilian study compared the 
clinical evidence of a myelopathy in 32 co-infected patients (HIV/
HTLV) with 118 patients singly infected with HIV, and found a 
higher incidence of signs of myelopathy in co-infected patients.4
Bhigjee et al. previously found a co-infection rate of HIV and 
HTLV-1 in 6% - 8% of patients with HAM. In a study on the 
spectrum of myelopathies in HIV positive patients in South Africa,5 
they found that 33% of patients had seropositivity for both HIV 
and HTLV-1, suggesting a higher frequency of myelopathy in 
co-infected patients. In addition, the patients were younger than 
those without HIV infection, but otherwise similar, without profound 
immunosuppression. 
Although the findings did not reach statistical significance, the 
tendency for HIV-positive patients to be symptomatic from HAM at 
a younger age is also suggested in our study, where 6/9 co-infected 
patients were younger than 40 years and only 2/11 patients under the 
age of 40 were singly infected with HTLV. A retrospective study from 
Louisiana15 evaluated HTLV 1 and 2 infection in HIV-positive patients, 
identifying 5 patients with HAM and HTLV-1 infection whose clinical 
findings were described, but not specifically compared with those of 
HIV-negative patients with HAM from the same unit. The patients’ 
ages ranged from 27 - 51 years, with 3 younger than 40 years. 
The reported incidence of cord atrophy in HAM varies from 
5.6% to 74%.17-18 Cord swelling may also occur, possibly in the 
earlier stages of disease.19 Measurements of the thoracic cord 
diameter in our patients showed that 80% of the HIV-negative 
group and 88% from the HIV-positive group showed atrophy 
of the cord on MRI – more than currently indicated in the 
literature. In addition to spinal cord abnormalities, white matter 
Fig. 1 MRI of patient 5 of the HIV-positive group to illustrate typical thoracic 
cord atrophy. The cord measured 4,4 mm at the T7 level.
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lesions in the brain have also been described in individuals 
with HAM.20 Only 3 of our 9 co-infected patients underwent 
brain imaging, but cerebral atrophy occurred in all 3, possibly 
reflecting the longstanding HIV infection. Only 1 showed white 
matter involvement. 
Conclusion
We found that patients co-infected with HIV and HTLV tended to 
have a younger age of onset, an earlier presentation to hospital and 
universal sphincter involvement, and commonly had evidence of 
spinal cord atrophy. In addition, when compared with other cases 
with dual infection described in the literature, our patients had a wide 
range of CD4 counts, indicating that HAM in HIV-positive patients 
may occur in cases of profound immunosuppression as well as early 
in the course of infection. The study is limited by the small number of 
patients assessed, and more data need to be collected to show possible 
statistical differences. 
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